[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 90 of about 90
6. Sohatee MA: A case of anaplastic large cell lymphoma: when you hear hoof beats, sometimes consider zebras, not horses. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic large cell lymphoma: when you hear hoof beats, sometimes consider zebras, not horses.
  • Following abdominal ultrasound and CT a lymph node and bone marrow biopsy were performed.
  • These investigations revealed the diagnosis to be anaplastic large cell lymphoma.
  • The patient consequently underwent a course of chemotherapy followed by a course of high-dose chemotherapy with an autologous bone marrow transplant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2002 Sep;41(3A):127-50 [12405944.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):736-42 [10929023.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • (PMID = 21918660.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029356
  •  go-up   go-down


7. Ng A, Hobson R, Williams D, Morland B: Anaplastic large cell lymphoma of bone--is it a bad tumor? Pediatr Blood Cancer; 2007 Apr;48(4):473-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma of bone--is it a bad tumor?
  • A teenage boy presented with a CD30-positive anaplastic large cell lymphoma (ALCL) affecting his scapula and was successfully treated with chemotherapy.
  • A further review of 11 ALCL cases with bony involvement treated in the UK since 1990, including two with primary bone disease, did not suggest an unfavorable treatment outcome.
  • This finding will need to be confirmed by further study on a larger patient cohort with primary bone ALCL.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Scapula / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078220.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 11
  •  go-up   go-down


8. Szomor A, Al Saati T, Delsol G, Kereskai L, Szijártó Z, Losonczy H: Primary bone marrow T-cell anaplastic large cell lymphoma with triple M gradient. Pathol Oncol Res; 2007;13(3):260-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone marrow T-cell anaplastic large cell lymphoma with triple M gradient.
  • We present a case of a 60-year-old male patient with primary bone marrow anaplastic large cell lymphoma.
  • Bone marrow biopsy showed massive CD30-positive, ALK-negative large lymphoid cell infiltration of T-cell origin with anaplastic morphology.
  • PCR analysis of lymphoid cells separated from the bone marrow demonstrated the presence of a B/T hybrid genotype disorder with no evidence of the t(2;5), nor t(1;2) translocations.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / immunology. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Humans. Immunoglobulin G / metabolism. Immunoglobulin M / metabolism. Male. Middle Aged

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922057.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


9. Bakshi NA, Ross CW, Finn WG, Valdez R, Ruiz R, Koujok K, Schnitzer B: ALK-positive anaplastic large cell lymphoma with primary bone involvement in children. Am J Clin Pathol; 2006 Jan;125(1):57-63
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive anaplastic large cell lymphoma with primary bone involvement in children.
  • We describe the clinical, radiologic, and pathologic features of primary bone anaplastic large cell lymphoma (ALCL) in 3 boys.
  • Bone was the only site of disease in 2 cases; an associated partial lymph node was involved in case 3.
  • Differential diagnoses included osteomyelitis and small round cell tumors of childhood, particularly Ewing sarcoma.
  • Two cases showed classic large pleomorphic cells; 1 showed a composite pattern with a distinct small cell component and the more typical large cell type.
  • Neoplastic cells in all cases showed strong CD30 and anaplastic lymphoma kinase expression with relatively weak epithelial membrane antigen positivity.
  • Two patients were disease-free at last follow-up (15 months and 11 years); 1 patient died of disseminated disease within a year of diagnosis.
  • ALCL should be considered a diagnostic possibility when evaluating neoplastic bone lesions in children.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482992.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


10. Naeem S, Bukhari MH, Khurshid I, Hameed A: Bone marrow involvement in systemic ALK+ anaplastic large cell lymphoma: morphological resemblance with Hodgkin's lymphoma. J Coll Physicians Surg Pak; 2006 Feb;16(2):148-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow involvement in systemic ALK+ anaplastic large cell lymphoma: morphological resemblance with Hodgkin's lymphoma.
  • Diagnosis of anaplastic large cell lymphoma was made on lymph node biopsy and confirmed by immunohistochemistry using a panel of monoclonal antibodies including ALK-1.
  • Bone marrow aspiration revealed the presence of large lymphoma cells and trephine biopsy showed interstitial involvement.
  • All these features resulted in a strong resemblance of the morphology with Hodgkin's lymphoma.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Bone Marrow / pathology. Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Anaplasia. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499814.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


11. Belousova IE, Kazakov DV, Sosna B, Sulc M, Michal M: [Small-cell variant of CD30+ -anaplastic large-cell lymphoma of the skin]. Arkh Patol; 2008 Mar-Apr;70(2):40-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small-cell variant of CD30+ -anaplastic large-cell lymphoma of the skin].
  • Three cases of the so-called variant of primary cutaneous CD30+ anaplastic large cell lymphoma (ALCL) are presented.
  • Microscopically, the tumors were composed of small cells with irregular nuclei that were immunohistochemically positive for CD3, CD5, CD7, and CD30 and negative for B-cell markers; there was focal ALK-1 positivity in 1 case.
  • Fhedium to large CD30+ cells were rarely found scattered in the infiltrate.
  • Chemotherapy was performed and finally the patient underwent allogenic bone marrow transplantation; he died 3 years after the original diagnosis due to acute graft-versus-host disease and sepsis.
  • [MeSH-major] Antigens, CD30. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD / immunology. Cell Size. Gene Rearrangement, B-Lymphocyte / immunology. Gene Rearrangement, T-Lymphocyte / immunology. Humans. Immunoglobulin Heavy Chains / immunology. Male. Middle Aged. Receptors, Antigen, T-Cell / immunology


12. Kisacik B, Akdogan A, Maras Y, Kalyoncu U, Karadag O, Kilickap S, Calguneri M: Anaplastic large cell lymphoma presenting with symmetric polyarthritis in pregnancy. Rheumatol Int; 2008 Jul;28(9):909-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma presenting with symmetric polyarthritis in pregnancy.
  • Anaplastic large-cell lymphoma (ALCL) is a rare T-cell lymphoma and typically is seen in children and young adults.
  • Primary bone infiltration of ALCL is exceedingly rare.
  • Herein we report ALCL of bone in a pregnant admitted with symmetric polyarthritis.
  • Excisional biopsy from the destructive mass showed anaplastic large cell lymphoma (CD 30 was positive and ALK negative).
  • [MeSH-major] Arthritis / etiology. Bone Neoplasms / complications. Lymphoma, Large-Cell, Anaplastic / complications. Pregnancy Complications, Neoplastic


13. Damm-Welk C, Schieferstein J, Schwalm S, Reiter A, Woessmann W: Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction. Br J Haematol; 2007 Aug;138(4):459-66
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.
  • Quantification of occult circulating tumour cells in blood or bone marrow (BM) enables the identification of patients with a high risk for relapse in nucleophosmin/anaplastic lymphoma kinase (NPM-ALK)-positive anaplastic large cell lymphoma (ALCL).
  • When ALCL cells were admixed with normal peripheral blood or BM, ALK- and CD30-positive cells could be detected above background level at an added concentration of 10(-5) for all three cell lines tested.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / analysis. Antigens, CD30 / immunology. Antigens, CD30 / metabolism. Bone Marrow Cells / chemistry. Costs and Cost Analysis. Flow Cytometry / economics. Flow Cytometry / methods. Humans. Nuclear Proteins / metabolism. Protein-Tyrosine Kinases / analysis. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / immunology. Protein-Tyrosine Kinases / metabolism. RNA, Messenger / analysis. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction / economics. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608768.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / Nuclear Proteins; 0 / RNA, Messenger; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


1
Advertisement
4. Weinberg OK, Seo K, Arber DA: Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary? Hum Pathol; 2008 Sep;39(9):1331-40
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary?
  • The frequency of bone marrow involvement in anaplastic large cell lymphoma has been reported with great variation.
  • A prior study found that anaplastic large cell lymphoma involvement of bone marrow was often not evident on routine stains and advocated using immunohistochemical studies.
  • We evaluated 70 bone marrow biopsies from 41 patients with anaplastic large cell lymphoma and found 10 morphologically involved cases (14% of all biopsies, 22% of all patients).
  • In most cases (9/10 biopsies), the involvement of the bone marrow by anaplastic large cell lymphoma was massive and, thus, was evident on the hematoxylin and eosin section.
  • To determine if the hematoxylin and eosin evaluation missed bone marrow involvement, we used a panel of antibodies including CD30, ALK-1, epithelial membrane antigen, and granzyme.
  • Only the 10 morphologically involved cases showed anaplastic large cell lymphoma cells with distinct CD30 expression.
  • Overall, marrow involvement in anaplastic large cell lymphoma was relatively uncommon, and when present, it was identified on hematoxylin and eosin sections.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602674.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


15. Lu Y, Zhao X, Wang E, Chen W, Huang Q: ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". Leuk Res; 2010 Apr;34(4):475-82
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase".
  • CD30-positive anaplastic large cell lymphoma (ALCL) is a distinctive malignant large cell lymphoma of T-cell lineage, often presenting in lymph node or extranodal sites.
  • ALCL cases with extensive bone marrow and peripheral blood involvement manifested as "leukemic phase" are extremely rare and the most of those cases reported are anaplastic large cell lymphoma kinase (ALK) positive ALCL in childhood population.
  • Here we report four adult cases of ALK-negative ALCL with extensive bone marrow and peripheral blood involvement manifested as "leukemic phase".
  • Circulating large lymphoma cells varied from 20 to 80% in peripheral blood and bone marrow biopsy showed various nodular or interstitial infiltrates.
  • By reviewing the clinicopathologic data of previously reported ALCL cases with extensive bone marrow and peripheral blood involvement, there appears to be of large variations in regard to the patient's age, morphologic variants, immunophenotypic or genotypic characteristics of the disease.
  • While most cases of ALCL with peripheral blood and bone marrow involvement were ALK-positive or carrying t(2;5) translocation, rare ALK-negative cases were also present.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19695703.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


16. Mussolin L, Pillon M, d'Amore ES, Santoro N, Lombardi A, Fagioli F, Zanesco L, Rosolen A: Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia; 2005 Sep;19(9):1643-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma.
  • Anaplastic large cell lymphoma (ALCL) harbors the reciprocal chromosomal translocation t(2;5)(p23;q35) in approximately 80% of the cases.
  • The genes involved are nucleophosmin (NPM) and anaplastic lymphoma kinase (ALK) and the resulting chimeric NPM-ALK protein is thought to play a key role in the pathogenesis of t(2;5) positive ALCL.
  • Few data on bone marrow (BM) involvement in ALCL have been published and they mostly rely on morphological examination of BM smears.
  • In 41 of the 47 cases we obtained the BM at diagnosis and investigated the prevalence of minimal BM infiltration by RT-PCR and real-time PCR.
  • These results suggest that minimal BM involvement at diagnosis is a common event in pediatric ALCL and that minimal BM disease monitoring could identify patients at risk of relapse.
  • [MeSH-major] Bone Marrow / metabolism. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049513.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


17. Flatland B, Fry MM, Newman SJ, Moore PF, Smith JR, Thomas WB, Casimir RH: Large anaplastic spinal B-cell lymphoma in a cat. Vet Clin Pathol; 2008 Dec;37(4):389-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large anaplastic spinal B-cell lymphoma in a cat.
  • A left axillary mass was identified, and the results of fine needle aspiration cytology indicated malignant round cell neoplasia of possible histiocytic origin.
  • The cells were large, had marked anisocytosis and anisokaryosis, occasional bi- and multinucleation, and cytoplasmic vacuolation.
  • Postmortem examination revealed spinal cord compression and an extradural mass at the C1-C2 spinal segment, with neoplastic cells in the adjacent vertebral bodies, surrounding skeletal muscle, left axillary lymph node, and bone marrow from the right femur.
  • The initial histologic diagnosis was anaplastic sarcoma, but immunohistochemical results indicated the cells were CD20+ and CD45R+ and CD3-, compatible with a diagnosis of B-cell lymphoma.
  • Clonality of the B-cell population could not be demonstrated using PCR testing for antigen receptor gene rearrangement.
  • To the authors' knowledge, this is the first reported case of a feline spinal anaplastic B-cell lymphoma exhibiting bi- and multinucleated cells.
  • The prognostic significance of this cell morphology and immunophenotype is unknown.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vet Clin Pathol. 2008 Dec;37(4):360-2 [19055569.001]
  • (PMID = 19055573.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Engsig FN, Møller MB, Hasselbalch HK, Mahdi B, Obel N: Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage. APMIS; 2007 Jun;115(6):778-83
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage.
  • Conventional pathological examination of bone marrow and lymph node biopsies did not demonstrate malignant cells and inflammatory disease was suspected.
  • Immunohistochemistry and cytogenetics postmortem led to a diagnosis of anaplastic large cell lymphoma (ALCL) of T-cell lineage.
  • [MeSH-major] Granulocytes / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neutrophils / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550390.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


19. Tamiolakis D, Papadopoulos N, Venizelos J, Kakagia D, Nikolaidou S, Bolioti S, Kouskoukis C: ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma. Onkologie; 2005 Jun;28(6-7):356-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma.
  • BACKGROUND: Anaplastic lymphoma kinase (ALK) expression has not been described in neutrophil-rich anaplastic large cell lymphoma (NR-ALCL).
  • CASE REPORT: A 12-year old female with a 4-weeks history of a non-resolving bump over the forehead resulting from injury, was diagnosed of stage IE cutaneous T-cell lymphoma, and radiation was employed.
  • Shortly after completion of therapy, there was progress of the disease on the soft tissue of the right hand, and bone marrow involvement was also found.
  • A fine-needle aspiration of the hand mass was performed, and a diagnosis of CD30+/ALK+ NR-ALCL, was rendered.
  • A panel of antibodies were used to establish diagnosis and subtyping.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, Large B-Cell, Diffuse / pathology. Neutrophils / pathology. Protein-Tyrosine Kinases / blood. Skin Neoplasms / blood. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933425.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


20. Benner MF, Willemze R: Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients. Br J Dermatol; 2008 Nov;159(5):1148-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients.
  • BACKGROUND: According to criteria of the World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas a diagnosis of primary cutaneous CD30-positive anaplastic large cell lymphoma (C-ALCL) should be made only when systemic localizations have been excluded by adequate staging procedures, including a bone marrow biopsy.
  • It has recently been questioned whether or not bone marrow examination should be performed routinely in indolent cutaneous lymphomas such as C-ALCL.
  • OBJECTIVES: To determine the incidence of bone marrow involvement in patients with an ALCL first presenting in the skin to find out if the current policy to advise bone marrow examination should be maintained or whether a bone marrow biopsy should be performed only in selected cases.
  • METHODS: All patients presenting with skin lesions with histological and immunophenotypical features of an ALCL were retrieved from the database of the Dutch Cutaneous Lymphoma Group.
  • Patients with a history of systemic ALCL and patients without bone marrow examination were excluded from the study.
  • RESULTS: Staging procedures showed the presence of extracutaneous disease in 20 patients, but bone marrow involvement was not detected in any of the 107 patients.
  • Moreover, only one patient developed bone marrow involvement during follow up (median follow-up period 69 months).
  • CONCLUSIONS: Bone marrow examination has limited value in the staging of patients with an ALCL first presenting in the skin, and should be performed only in selected cases.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782320.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Vaid R, Cohen B: Primary cutaneous CD30 positive anaplastic large cell lymphoma in an adolescent. Pediatr Dermatol; 2009 Nov-Dec;26(6):721-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous CD30 positive anaplastic large cell lymphoma in an adolescent.
  • We present a case of a 14-year-old boy with a large ulcerated plaque on the scalp for 6 months, who was found to have primary cutaneous CD30-positive, anaplastic kinase-negative, anaplastic large cell lymphoma with post-auricular lymphadenopathy.
  • MRI, bone marrow biopsy, and laboratory data demonstrated no other systemic involvement.
  • Very few cases of primary cutaneous CD30-positive anaplastic large cell lymphoma in the pediatric population have been reported, and our case represents one of the first pediatric patients with local lymph node involvement.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Scalp / metabolism. Scalp / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20199449.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


22. Takahashi D, Nagatoshi Y, Nagayama J, Inagaki J, Itonoaga N, Takeshita M, Okamura J: Anaplastic large cell lymphoma in leukemic presentation: a case report and a review of the literature. J Pediatr Hematol Oncol; 2008 Sep;30(9):696-700
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma in leukemic presentation: a case report and a review of the literature.
  • It is extremely rare that a patient with anaplastic large cell lymphoma (ALCL) demonstrates circulating lymphoma cells.
  • The white cell count was 26.2x10(9)/L with 95% of abnormal lymphoid cells, which were small to medium-sized with a high nucleus/cytoplasm ratio, basophilic cytoplasm, condensed nuclear chromatins, and 1 or 2 distinct nucleoli, hemoglobin 6.4 g/dL, and platelet 0.9x10(9)/L.
  • A flow cytometric analysis of abnormal cells in both the peripheral blood and bone marrow samples was strongly positive for CD30 on their cell membranes.
  • Reverse transcriptase-polymerase chain reaction of peripheral blood cell-derived mRNA also indicated the fusion gene product of anaplastic lymphoma kinase and nucleophosmin.
  • [MeSH-major] Leukemia / diagnosis. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Antigens, CD30 / analysis. Bone Marrow Examination. Child. Fatal Outcome. Humans. Male. Protein-Tyrosine Kinases. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776764.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 25
  •  go-up   go-down


23. Lü Z, Shi YK, He XH, Qin Y, Zhou SY, Zhang CG, Liu P, Yang JL: [Primary cutaneous anaplastic large cell lymphoma: clinical presentation, therapy and prognosis study of 10 cases]. Zhonghua Yi Xue Za Zhi; 2010 May 11;90(18):1247-50
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutaneous anaplastic large cell lymphoma: clinical presentation, therapy and prognosis study of 10 cases].
  • OBJECTIVE: To explore the clinical presentation, therapy and prognosis study of primary cutaneous anaplastic large cell lymphoma (PCALCL).
  • Two patients had lymphadenopathy and one had bone involvement with anaplastic lymphoma kinase (ALK) positive and high cell proliferation ratio index (ki-67 > 80%).
  • [MeSH-major] Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnosis. Lymphoma, Primary Cutaneous Anaplastic Large Cell / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646596.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Siebert S, Amos N, Williams BD, Lawson TM: Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome. Semin Arthritis Rheum; 2007 Aug;37(1):63-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome.
  • Our aim was to describe a case of primary hepatic anaplastic large-cell lymphoma (ALCL) presenting as a rheumatic syndrome.
  • Despite a high clinical suspicion of underlying malignancy, repeated radiologically guided biopsies of bone and liver abnormalities failed to demonstrate any malignant cells.
  • There are a few reports of ALCL presenting as bone lesions, but to our knowledge this is the first report of hepatic ALCL presenting with a rheumatic syndrome.
  • The tumor produced large quantities of the proinflammatory cytokines interleukin-6 (IL-6) and IL-8 but did not produce tumor necrosis factor-alpha (TNF-alpha), IL-1, or IL-4.
  • The ALCL tissue in our patient produced large quantities of the IL-6, which we believe was associated with the patient's systemic inflammation.
  • [MeSH-major] Interleukin-6 / metabolism. Liver Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Rheumatic Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Middle Aged


25. Sevilla DW, Choi JK, Gong JZ: Mediastinal adenopathy, lung infiltrates, and hemophagocytosis: unusual manifestation of pediatric anaplastic large cell lymphoma: report of two cases. Am J Clin Pathol; 2007 Mar;127(3):458-64
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal adenopathy, lung infiltrates, and hemophagocytosis: unusual manifestation of pediatric anaplastic large cell lymphoma: report of two cases.
  • To date, only 1 report describes an anaplastic large cell lymphoma (ALCL) associated with hemophagocytosis in the pediatric population.
  • Bone marrow biopsies and aspirates revealed striking hemophagocytosis but no ALCL.
  • Definitive diagnosis required lymph node biopsies that showed CD30+, anaplastic lymphoma kinase-l+ ALCL.
  • Both tumors responded to standard lymphoma chemotherapy.
  • [MeSH-major] Lung Diseases / pathology. Lymphatic Diseases / pathology. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Activin Receptors, Type II / genetics. Antigens, CD30 / analysis. Antigens, CD8 / analysis. Child. Child, Preschool. Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 5. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mediastinum. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276937.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD8; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


26. Pant V, Jambhekar NA, Madur B, Shet TM, Agarwal M, Puri A, Gujral S, Banavali M, Arora B: Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases. Indian J Pathol Microbiol; 2007 Apr;50(2):303-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases.
  • This study highlights the rare presentation of anaplastic large cell lymphoma as primary bone and soft tissue tumour.
  • Clinical impression was non Hodgkin's lymphoma in 4 cases, sarcoma in 6 (osteosarcoma-2, Ewing's/primitive neuroectodermal tumour-1, and sarcoma NOS-3), and tuberculosis of thoracic spine in 1 and the last case involving the rib had a differential diagnosis of tuberculosis and NHL.
  • The pleomorphic cytomorphology ofALCL leads to confusion with the more frequent bone and soft tissue sarcomas affecting the musculoskeletal system.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Activin Receptors, Type II / metabolism. Adolescent. Adult. Antigens, CD30 / metabolism. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male


27. Kim YC, Yang WI, Lee MG, Kim SN, Cho KH, Lee SJ, Lee MW, Koh JK: Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea. Int J Dermatol; 2006 Nov;45(11):1312-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.
  • AIM: To elucidate the possible association of EBV with CD30+ anaplastic large cell lymphoma (ALCL) involving the skin and lymphomatoid papulosis (LyP) in South Korea.
  • The other was CD30+ ALCL involving the skin and other organs, including lymph nodes, bone, lung, and spleen.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human / growth & development. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphomatoid Papulosis / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17076712.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Antigens, CD30; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr virus encoded RNA 1; 0 / Epstein-Barr virus encoded RNA 2; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


28. Damm-Welk C, Busch K, Burkhardt B, Schieferstein J, Viehmann S, Oschlies I, Klapper W, Zimmermann M, Harbott J, Reiter A, Woessmann W: Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood; 2007 Jul 15;110(2):670-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma.
  • Clinical and histopathological characteristics have limited prognostic value for children with anaplastic large-cell lymphoma (ALCL).
  • We evaluated the presence, extent, and prognostic impact of circulating tumor cells in bone marrow (BM) and peripheral blood (PB) of children and adolescents with NPM-ALK-positive ALCL at diagnosis using qualitative and quantitative polymerase chain reaction (PCR) for NPM-ALK.
  • [MeSH-major] Bone Marrow Cells / physiology. Lymphoma, Large B-Cell, Diffuse / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392503.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


29. Cesaro S, Pillon M, Visintin G, Putti MC, Gazzola MV, D'Amore E, Scarzello G, Zanesco L, Messina C, Rosolen A: Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series. Eur J Haematol; 2005 Jul;75(1):22-6
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series.
  • OBJECTIVES: The use of allogeneic stem cell transplantation in NHL patients is not yet clearly defined, especially in children and adolescents, but this option offers the advantages of a tumor-free graft and the possible induction of a graft-vs.-tumor effect.
  • PATIENTS AND METHODS: We report the results of four consecutive pediatric patients affected by anaplastic large cell lymphoma (ALCL) and treated with allogeneic stem cell transplantation from an unrelated donor.
  • CONCLUSIONS: The increasing number of volunteer bone marrow donors and the reduced toxicity of unrelated stem cell transplantation, especially in children, make this therapeutic option worth more extensive investigation in the treatment of high-risk failure ALCL, although more data is needed to evaluate the long-term benefits.
  • In this regard, the presence of factors predictive of worst outcome such as an early relapse (within 12 months from diagnosis), a refractory or relapsing ALCL and the persistent detection on blood or bone marrow of nucleophosmin-anaplastic lymphoma kinase protein (NPM-ALK) transcript may help select the patients eligible to allogeneic related or unrelated stem cell transplantation.
  • [MeSH-major] Bone Marrow Transplantation. Lymphoma, Large B-Cell, Diffuse / therapy


30. Ben Barak A, Elhasid R, Ben Itzhak O, Ben Arieh Y, Zaidman I, Haimi M, Bar-Joseph G, Ben Arush MW: Infant anaplastic lymphoma: case report and review of the literature. Pediatr Hematol Oncol; 2007 Jul-Aug;24(5):379-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infant anaplastic lymphoma: case report and review of the literature.
  • Anaplastic large cell lymphoma (ALCL) is a well-known entity, but there are no data on prognosis according to the age of the patient, especially in infants.
  • Cervical lymph node biopsy revealed anaplastic lymphoma with positive staining to ALK 1 and TIA 1.
  • Immunophenotypic analysis of peripheral and bone marrow lymphoid cells showed an aberrant T-cell immunophenotype, including expression of CD3, CD45R0+, CD43+, and CD30+.
  • Cytogenetic analysis performed on blood and bone marrow samples demonstrated the translocation t(2;5) (p23;q35), and trisomy 47.
  • This report is of a rare case of infant anaplastic lymphoma and excellent response to treatment.
  • More reports of similar cases may determine the cause and prognosis of such children, helping to tailor therapy according to the age of the child and other prognostic factors, especially bone marrow involvement.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613884.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


31. Park SJ, Kim S, Lee DH, Jeong YP, Bae Y, Han EM, Huh J, Suh C: Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center. Yonsei Med J; 2008 Aug 30;49(4):601-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic anaplastic large cell lymphoma in Korean adults: 11 years' experience at Asan Medical Center.
  • PURPOSE: Anaplastic large cell lymphoma (ALCL), a CD30+ T-cell non-Hodgkin's lymphoma, represents only 2-8% of lymphoma overall.
  • The most commonly involved extranodal sites were bone (n = 7) and soft tissue (n = 6).
  • Univariate analysis showed that performance status (p = 0.035), international prognostic index (IPI) (p = 0.025), and age-adjusted IPI (p = 0.034) were significant prognostic factors for OS, whereas anaplastic lymphoma kinase (ALK) expression did not affect OS (p = 0.483).
  • [MeSH-major] Hospitals. Lymphoma, Large-Cell, Anaplastic / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):633-8 [16891805.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):172-8 [11391714.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5623-37 [11607814.001]
  • [Cites] Hematol Oncol. 2001 Dec;19(4):129-50 [11754390.001]
  • [Cites] J Pathol. 2003 May;200(1):4-15 [12692835.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1727-31 [14692525.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Br J Haematol. 1990 Feb;74(2):161-8 [2156548.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):943-9 [7683712.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Blood. 1995 Jan 1;85(1):1-14 [7803786.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):955-62 [8622045.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):319-27 [8819081.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3727-34 [9345059.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Haematologica. 1999 May;84(5):425-30 [10329921.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Histopathology. 2006 Apr;48(5):481-504 [16623775.001]
  • [Cites] Hematol Oncol. 1999 Dec;17(4):137-48 [10725869.001]
  • (PMID = 18729302.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2615286
  •  go-up   go-down


32. Ziarkiewicz-Wróblewska B, Górnicka B, Gierej B, Suleiman W, Nowacka-Cieciura E, Durlik M, Bogdańska M, Wasiutyński A, Pileri SA: Hodgkin-like lymphoma, simulating anaplastic large cell lymphoma in the patient after renal transplantation--unusual case report and literature review. Pol J Pathol; 2008;59(1):63-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin-like lymphoma, simulating anaplastic large cell lymphoma in the patient after renal transplantation--unusual case report and literature review.
  • It was evaluated only by bone marrow biopsy, which showed its total involvement with malignant lymphoma.
  • It was composed of two populations of lymphoid cells: large RS-like cells and small to medium ones, with slightly angular nuclei without visible nucleoli.
  • Both cellpopulations did not show positive reaction for typical B cell markers (CD20, CD79a).
  • Large RS-like cells were positive with CD30 and EBV-LMP.
  • However, negative reaction with CD15 and positive reactions with UCHL1 and EMA were not consistent with classical type of Hodgkin lymphoma.
  • Morphological picture and immunophenotype had suggested anaplastic T cell lymphoma.
  • Because of negative reaction with ALK1, initial diagnosis was ALCL ALK-negative.
  • Taking it into account the diagnosis was changed; finally Hodgkin-like B lymphoma was diagnosed.
  • 2. Negative reactions with typical immunohistochemical markers for lymphocytes of B cell line do not exclude the possibility of B-cell proliferation.
  • [MeSH-major] Hodgkin Disease / diagnosis. Kidney Transplantation / adverse effects. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Biomarkers, Tumor / metabolism. Bone Marrow / metabolism. Bone Marrow / pathology. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / pathology. Ganciclovir / therapeutic use. Humans. Immunosuppression. Male. Middle Aged. Postoperative Complications. Prednisone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use


33. Siordia-Reyes AG, Ferman-Cano F, Rodríguez-Velasco A: [ALK-1 positive anaplastic large cell lymphoma of the lung. Report of a pediatric case]. Gac Med Mex; 2005 Nov-Dec;141(6):531-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ALK-1 positive anaplastic large cell lymphoma of the lung. Report of a pediatric case].
  • Ki-1 anaplastic large cell non-Hodgkin lymphoma is a well recognized clinical entity.
  • In the extranodal disease, which occurs in approximately half of the cases, the skin is the most common site; bone marrow, lung and central nervous system are generally not involved.
  • Anaplastic large cell lymphoma is more common among young people, in whom the prognosis is more favorable.
  • Primary anaplastic large cell lymphoma of the lung is a rare clinical entity.
  • Its clinical expression is similar to a high grade malignant lymphoma, and in most cases the diagnosis is made in advanced stages.
  • We present a pediatric case with ALK-1 positive anaplastic large cell lymphoma of the lung.
  • [MeSH-major] Lung Neoplasms / chemistry. Lymphoma, Large B-Cell, Diffuse / chemistry. Membrane Proteins / analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381509.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  • [Number-of-references] 16
  •  go-up   go-down


34. Sano F, Tasaka T, Nishimura H, Akiyama T, Kubo Y, Matsuhashi Y, Wada H, Sugihara T, Sadahira Y: Small cell variant of anaplastic large cell lymphoma diagnosed by a novel chromosomal abnormality t(2;5;3)(p23;q35;p21) of bone marrow cells. Pathol Int; 2008 Aug;58(8):494-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant of anaplastic large cell lymphoma diagnosed by a novel chromosomal abnormality t(2;5;3)(p23;q35;p21) of bone marrow cells.
  • Because of the rarity and the morphological variations, small cell variant of anaplastic large cell lymphoma (ALCL) represents a diagnostic challenge.
  • Herein is reported a case of leukemic type of small cell variant of ALCL, in which the diagnosis was established by a cytogenetic analysis.
  • The initial differential diagnosis on bone marrow trephine biopsy sections included viral infection and peripheral T-cell lymphoma unspecified.
  • But a cytogenetic study on bone marrow cells indicated a novel complex translocation, t(2;5;3)(p23;q35;p21), which led to confirmation of anaplastic lymphoma kinase (ALK)-positive pleomorphic small to medium-sized cells scattered in bone marrow cells, on immunohistochemistry.
  • The patient achieved complete remission after four courses of combination chemotherapy, and received autologous peripheral stem cell transplantation (auto-PBSCT) after two additional courses of combination chemotherapy, but relapsed 2 months after auto-PBSCT in the bilateral lung.
  • Allogeneic stem cell transplantation led to a second remission.
  • This case demonstrates the diagnostic importance of cytogenetic study for malignant lymphoma involving bone marrow.
  • [MeSH-major] Bone Marrow Cells / pathology. Chromosomes, Human, 1-3 / genetics. Chromosomes, Human, Pair 5 / genetics. Lymphoma, Large-Cell, Anaplastic / diagnosis. Translocation, Genetic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Chromosome Banding. Diagnosis, Differential. Female. Humans. Lymphoma, T-Cell, Peripheral / diagnosis. Protein-Tyrosine Kinases / immunology. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Remission Induction. Spectral Karyotyping. Virus Diseases / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Small Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705769.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


35. Rupani A, Modi C, Desai S, Rege J: Primary anaplastic large cell lymphoma of central nervous system--a case report. J Postgrad Med; 2005 Oct-Dec;51(4):326-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic large cell lymphoma of central nervous system--a case report.
  • Central nervous system (CNS) involvement is extremely rare in anaplastic large cell lymphoma (ALCL).
  • MRI showed a well- circumscribed lesion in the right fronto-parietal lobe eroding the skull bone.
  • Biopsy showed large pleomorphic cells.
  • Hence a high level of suspicion is essential for early diagnosis and for instituting appropriate treatment.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adolescent. Diagnostic Errors. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tuberculosis / diagnosis


36. Palraj B, Paturi A, Stone RG, Alvarez H, Sebenik M, Perez MT, Bush LM: Soft tissue anaplastic large T-cell lymphoma associated with a metallic orthopedic implant: case report and review of the current literature. J Foot Ankle Surg; 2010 Nov-Dec;49(6):561-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue anaplastic large T-cell lymphoma associated with a metallic orthopedic implant: case report and review of the current literature.
  • When encountered, such malignancies are most often sarcoma, but rarely B-cell non-Hodgkin's lymphoma has also been described.
  • In this article, we describe what we believe to be the first published case of anaplastic large T-cell lymphoma associated with a stainless steel fixation plate that was implanted several years earlier for repair of a tibial fracture.
  • [MeSH-major] Bone Plates / adverse effects. Lymphoma, Large-Cell, Anaplastic / diagnosis. Soft Tissue Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20870426.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 12597-68-1 / Stainless Steel
  •  go-up   go-down


37. Liu T, He M, Carlson DL, Hedvat C, Teruya-Feldstein J: ALK-positive anaplastic large cell lymphoma in a patient with chronic lymphocytic leukemia. Int J Surg Pathol; 2010 Oct;18(5):424-8
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive anaplastic large cell lymphoma in a patient with chronic lymphocytic leukemia.
  • This article reports the case of a 59-year-old patient with an 8-year history of chronic lymphocytic leukemia (CLL), prostate carcinoma, and squamous cell carcinoma who developed an ALK-positive anaplastic large cell lymphoma (ALCL).
  • Lymph node and bone marrow biopsies showed 2 distinct morphologic populations: (a) the CLL component showing a diffuse monomorphous infiltrate of small lymphocytes with the typical immunophenotype showing positive CD20, CD5, CD23, and κ light chain restriction and (b) the ALCL component showing large anaplastic pleomorphic cells positive for CD30, CD45, ALK, CD45Ro, CD4, and vimentin.
  • Polymerase chain reaction performed on the lymph node for immunoglobulin heavy chain and T-cell receptor γ and β showed gene rearrangements after macrodissection of morphologically distinct populations, indicating confirmed genetically distinct populations.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Multiple Primary. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Cells / pathology. DNA, Neoplasm / genetics. Fatal Outcome. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Lymph Nodes / pathology. Male. Middle Aged. Receptor Protein-Tyrosine Kinases

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794171.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


38. Alsop S, Sanger WG, Elenitoba-Johnson KS, Lim MS: Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma. Hum Pathol; 2007 Oct;38(10):1576-80
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma.
  • CML occurring as a secondary malignancy in individuals treated for anaplastic large cell lymphoma (ALCL) is also rare.
  • Four years after receiving treatment for ALCL, he presented with a swollen leg and a white cell count of 431,000.
  • Peripheral blood and bone marrow evaluation revealed a myeloproliferative disorder.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Second Primary / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Flow Cytometry. Fusion Proteins, bcr-abl / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Orbital Neoplasms / pathology. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use


39. Grewal JS, Smith LB, Winegarden JD 3rd, Krauss JC, Tworek JA, Schnitzer B: Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol; 2007 Jul;86(7):499-508
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature.
  • Anaplastic large cell lymphoma (ALCL) is an aggressive neoplasm of T- or null cell phenotype and is recognized as a distinct clinicopathologic subtype of non-Hodgkin lymphoma (NHL) in the revised World Health Organization (WHO) classification of hematopoietic neoplasms.
  • Most cases with leukemic involvement are the small cell variant of ALCL.
  • The patients presented with massive extranodal disease involving cerebrospinal fluid (CSF), liver, spleen, lungs, and bone marrow.
  • Two of the patients had small cell variant and the third patient had common type ALCL.
  • The neoplastic cells in all three patients were ALK positive; however these patients died within months of diagnosis.
  • Some, but not all, cases in the literature presenting with peripheral blood involvement had small cell variant ALCL, as seen in two of our cases.
  • The leukemic phase of ALCL should be considered when a T-cell leukemia with unusual morphologic features is encountered.
  • [MeSH-major] Leukemia / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396261.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 91
  •  go-up   go-down


40. Kalinova M, Krskova L, Brizova H, Kabickova E, Kepak T, Kodet R: Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status. Leuk Res; 2008 Jan;32(1):25-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
  • Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of malignant lymphoproliferative diseases with a consistent expression of the cytokine receptor CD30.
  • Real-time quantitative RT-PCR (RQ-RT-PCR) of NPM/ALK and CD30 gene expression was employed to analyze minimal residual disease (MRD) in 10 patients with NPM/ALK positive ALCL in 79 follow-up bone marrow (BM) and/or peripheral blood (PB) samples.
  • [MeSH-major] Antigens, CD30 / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Neoplasm, Residual / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320171.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


41. Joshi A, Fields P, Simo R: Anaplastic lymphoma of the cervical esophagus presenting as a tracheoesophageal fistula. Head Neck; 2008 Sep;30(9):1264-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma of the cervical esophagus presenting as a tracheoesophageal fistula.
  • BACKGROUND: Anaplastic kinase-1 positive lymphoma (ALK-1) is a very rare but distinct pathologic entity.
  • ALK-1 lymphoma tends to affect the bone marrow, skin, lungs, soft tissue, but very rarely the gastrointestinal tract.
  • METHODS: We report a case of ALK-1 positive lymphoma presenting as a tracheoesophageal fistula.
  • CONCLUSION: ALK-1 positive lymphoma of the upper aerodigestive involvement is extremely rare.
  • Histopathologic analysis can be difficult and immunohistochemical studies will aid are of paramount importance in the diagnosis and help in subsequent management and also act as prognostic indicators.
  • [MeSH-major] Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / therapy. Tracheoesophageal Fistula / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Cervical Vertebrae. Combined Modality Therapy. Diagnosis, Differential. Esophagoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Photomicrography. Risk Assessment. Salvage Therapy. Stem Cell Transplantation / methods. Tomography, X-Ray Computed. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Tracheoesophageal fistula.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18228520.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Park SR, Baek JY, Kim DW, Im SA, Kim TY, Bang YJ, Kim NK, Jeon YK, Kim CW, Heo DS: Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. J Korean Med Sci; 2006 Aug;21(4):633-8
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
  • Despite advances in the characterization of anaplastic large cell lymphoma (ALCL), little data is available on Asian patients.
  • Ann Arbor stage III-IV, B symptoms, high-intermediate/ high International Prognostic Index (IPI), and extranodal disease at diagnosis were present in 56%, 44%, 41%, and 63%, respectively.
  • Compared with Western studies, the male/female ratio (4.3) was markedly higher and skin (9%) and bone involvement (9%) were less frequent.
  • The staining results for anaplastic lymphoma kinase were positive in 6 (33%) of 18 cases available.
  • Our data suggest that Korean ALCL patients appear to have a higher male/female ratio, less frequent skin/bone involvement, and lower CR rate compared with those of Western studies.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Nov 1;90(9):3727-34 [9345059.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):806-12 [9708949.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S56-67 [9894470.001]
  • [Cites] Aust N Z J Med. 1998 Dec;28(6):790-4 [9972408.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2688-96 [10194449.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Haematologica. 1999 May;84(5):425-30 [10329921.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1727-31 [14692525.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):23-33 [2456620.001]
  • [Cites] Br J Haematol. 1989 Jan;71(1):31-6 [2917127.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2604-12 [8453584.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):937-42 [8387578.001]
  • [Cites] Br J Haematol. 1994 Mar;86(3):513-23 [7519036.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):955-62 [8622045.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):319-27 [8819081.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1420-32 [9414185.001]
  • (PMID = 16891805.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Other-IDs] NLM/ PMC2729883
  •  go-up   go-down


43. Lowe EJ, Sposto R, Perkins SL, Gross TG, Finlay J, Zwick D, Abromowitch M, Children's Cancer Group Study 5941: Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer; 2009 Mar;52(3):335-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) is characterized by advanced disease at presentation (70-80% of pediatric cases) and accounts for 10-15% of all childhood lymphomas.
  • METHODS: CCG-5941 used a compressed aggressive multiagent T-cell lineage chemotherapy regimen consisting of a 3-week induction therapy (vincristine, prednisone, cyclophosphamide, daunomycin, asparaginase) followed by a 3-week consolidation period (vincristine, prednisone, etoposide, 6-thioguanine, cytarabine, asparaginase, methotrexate) followed by six courses of maintenance chemotherapy at 7-week intervals (cyclophosphamide, 6-thioguanine, vincristine, prednisone, doxorubicin, asparaginase, methotrexate etoposide, cytarabine).
  • Extranodal disease was common (mediastinum 35%, skin 15%, lung 14%, bone 12%, bone marrow 13%, liver 6%, and other viscera 17%).
  • Relapse occurred early with 17 (81%) relapses occurring within 2 years of diagnosis and 12 (57%) while receiving therapy.
  • Univariate analysis for risk factors only identified bone marrow involvement predicting lower EFS (P = 0.03).

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):812-20 [12060115.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):895-8 [8164039.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2467-71 [7919366.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3727-34 [9345059.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):541-7 [15659500.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1643-7 [16049513.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2133-40 [16211546.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):624-7 [16351638.001]
  • [Cites] Blood. 2007 Jul 15;110(2):670-7 [17392503.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • (PMID = 18985718.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-06; United States / NCI NIH HHS / CA / U10 CA098543-06
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS123401; NLM/ PMC2769495
  •  go-up   go-down


44. Lagmay J, Termuhlen A, Fung B, Ranalli M: Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient. J Pediatr Hematol Oncol; 2009 May;31(5):330-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient.
  • Anaplastic large cell lymphoma is a heterogeneous group of malignant non-Hodgkin lymphomas that occurs in up to 15% of all pediatric non-Hodgkin lymphomas.
  • It is characterized by B-symptoms and involvement of extranodal sites such as skin, bone, and soft tissue.
  • This brief report describes first reported case of pediatric primary testicular anaplastic large cell lymphoma in a 14-year-old boy.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / metabolism. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antigens, CD30 / metabolism. Biomarkers, Tumor / metabolism. Biopsy. Cell Nucleus / metabolism. Cell Nucleus / pathology. Golgi Apparatus / metabolism. Golgi Apparatus / pathology. Humans. Male. Orchiectomy. Testis / pathology. Testis / surgery

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415011.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


45. Bollag R, Ramalingam P, Davis B, Reid-Nicholson M: Fine needle aspiration cytology of an endotracheal mass: report of a case with an unusual presentation of anaplastic large cell lymphoma. Acta Cytol; 2010 May-Jun;54(3):328-32
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of an endotracheal mass: report of a case with an unusual presentation of anaplastic large cell lymphoma.
  • BACKGROUND: Anaplastic large cell lymphoma (ALCL) is an uncommon hematolymphoid neoplasm characterized by malignant lymphocytes of T-cell phenotype.
  • In this location the diagnosis of ALCL can be especially difficult as its pleomorphic cytomorphology mimics that of a carcinoma, which is a more typical neoplasm arising in the trachea.
  • Imaging revealed an endotracheal mass and multiple lytic bone lesions.
  • Immunohistochemical studies confirmed the diagnosis of ALCL.
  • While its cytologic features are straightforward, a high index of suspicion is necessary to ensure accurate diagnosis when it presents in unusual locations.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Tracheal Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518421.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


46. Matsushita H, Nakamura N, Asai S, Yabe M, Hayama N, Kondo Y, Urano T, Miyachi H: A leukemic change as an initial manifestation of the common variant type of ALK-positive anaplastic large cell lymphoma in a patient with lung adenocarcinoma. Intern Med; 2008;47(23):2057-62
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A leukemic change as an initial manifestation of the common variant type of ALK-positive anaplastic large cell lymphoma in a patient with lung adenocarcinoma.
  • We report an 81-year-old man who had leukemic presentation of ALK-positive anaplastic large cell lymphoma (ALCL) as an initial manifestation.
  • The peripheral blood smear and bone marrow aspiration revealed the infiltration of atypical large cells with horseshoe-shaped or lobulated nuclei.
  • The detection of CD30 expression and the t (2;5) (p23;q35) translocation in these cells was confirmatory of a diagnosis of common variant ALK-positive ALCL in a leukemic phase.
  • An adequate, prompt diagnosis is necessary for this rare disease status in oncologic emergency to improve the disease management.
  • [MeSH-major] Adenocarcinoma / diagnosis. Genetic Variation / genetics. Lung Neoplasms / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antigens, CD30 / genetics. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043261.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Number-of-references] 20
  •  go-up   go-down


47. Bhagavathi S, Fu K: Primary bone lymphoma. Arch Pathol Lab Med; 2009 Nov;133(11):1868-71
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for primary bone lymphoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone lymphoma.
  • Primary bone lymphomas are rare, even though secondary involvement of the bone marrow is a common event in systemic lymphomas.
  • Most primary bone lymphomas are primary bone diffuse large B-cell lymphomas (PBDLBCLs) with a rare occurrence of follicular, marginal zone, anaplastic large cell, Hodgkin, and T-cell lymphomas.
  • The patients present with bone pain, palpable mass, fractures, or neurologic symptoms.
  • Morphologically, the lymphoma consists of a polymorphous mixture of small to large cells with multilobated nuclei, fine chromatin, and inconspicuous to prominent nucleoli.
  • Differential diagnoses for PBDLBCL include chronic osteomyelitis, primary bone sarcoma, leukemic infiltrate, Ewing sarcoma, metastatic sarcomas, and carcinoma.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Carcinoma / diagnosis. Carcinoma / secondary. Chronic Disease. Diagnosis, Differential. Humans. Leukemic Infiltration / diagnosis. Osteomyelitis / diagnosis. Osteosarcoma / diagnosis. Osteosarcoma / secondary. Sarcoma, Ewing / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for bone lymphoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886726.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


48. Monaco S, Tsao L, Murty VV, Nandula SV, Donovan V, Oesterheld J, Bhagat G, Alobeid B: Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase. Am J Hematol; 2007 Jan;82(1):59-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase.
  • Pediatric ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is usually associated with a favorable prognosis.
  • Similar to other rare cases described in the literature, it followed an aggressive clinical course despite multiple regimens of chemotherapy and bone marrow transplantation.
  • Lymphoma cells showed aberrant ALK expression and c-myc overexpression.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Chromosomes, Human, Pair 8 / genetics. Gene Rearrangement. Leukemia / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955462.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


49. Beltran B, Castillo J, Salas R, Quiñones P, Morales D, Hurtado F, Riva L, Winer E: ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol; 2009;2:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature.
  • BACKGROUND: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL).
  • Two cases had primary extranodal disease (multifocal bone and right nasal fossa).
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2009 Jan;40(1):75-82 [18755494.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Clin Pathol. 2001 Mar;115(3):396-403 [11242796.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1285-8 [15492998.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Pol J Pathol. 2005;56(1):37-45 [15921012.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):357-63 [16091196.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1839-40 [16107887.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):390-1 [16086416.001]
  • [Cites] Rinsho Ketsueki. 2005 Jul;46(7):501-6 [16440742.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):649-53 [15852431.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):493-505 [16794633.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2006 Sep;35(9):529-34 [17134546.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):940-5 [17509395.001]
  • [Cites] Eur J Haematol. 2007 Aug;79(2):166-9 [17635242.001]
  • [Cites] Cancer. 2007 Aug 25;111(4):224-33 [17554754.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2573-80 [18089849.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):126-44 [18039352.001]
  • [Cites] Korean J Lab Med. 2008 Apr;28(2):89-94 [18458503.001]
  • [Cites] Biochem J. 2008 Jun 15;412(3):415-23 [18498251.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):108-13 [18220322.001]
  • (PMID = 19250532.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 39
  • [Other-IDs] NLM/ PMC2651189
  •  go-up   go-down


50. Choung HS, Kim HJ, Kim WS, Kim K, Kim SH: [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement]. Korean J Lab Med; 2008 Apr;28(2):89-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytomorphology and molecular characterization of CLTC-ALK rearrangement in 2 cases of ALK-positive diffuse large B-cell lymphoma with extensive bone marrow involvement].
  • Aanaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is an unusual disease entity first reported in 1997 as DLBCL with expression of full-length ALK protein.
  • Immunohistochemical studies on the lymph nodes revealed large sized neoplastic cells with plasmablastic differentiation, which were negative for CD30 and positive for ALK with the characteristic granular staining in the cytoplasmic region.
  • Extensive involvement of bone marrow was observed in both cases showing large, extremely atypical cells.
  • Fluorescence in situ hybridization and molecular studies on the bone marrow aspirate specimens led to the detection of a clathrin (CLTC)/ALK rearrangement.
  • Despite aggressive chemotherapy, the patients died 15 and 17 months after the diagnosis, indicating poor prognosis of the disease entity.
  • This is the first report demonstrating the cytomorphologic findings of ALK-positive DLBCL cells on bone marrow aspirates.
  • [MeSH-major] Bone Marrow / pathology. Clathrin / genetics. Gene Fusion. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458503.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Clathrin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


51. Rudzki Z, Rucińska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczyk M, Włodarska I, Stachura J: ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol; 2005;56(1):37-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare, recently defined tumor distinct in many aspects from ALK-positive anaplastic large cell lymphoma (ALCL).
  • A 48-year old man presented with a large upper neck mass growing slowly over 18 months.
  • Histologically the tumor was diagnosed as an ALK-positive diffuse large B-cell lymphoma. with plasmablastic features.
  • Large, frequently intrasinusoidal tumor cells expressed CD138, EMA, weakly IgA and kappa, but were negative for other B-cell markers, T-cell markers and CD30.
  • At the diagnosis the patient manifested with the stage IIIB.
  • The patient died of massive bleeding from his decomposing tumor 3 months after the diagnosis.
  • The tumor showed immunoblastic/anaplastic morphology, with some Reed-Sternberg-like cells positive for ALK.
  • ALK-positive DLBCL affects mostly middle-aged men, shows generally poor but stage-dependent prognosis (at least 60% mortality rate), presents typically as a lymph node-based disseminated disease, and very rarely involves the bone marrow.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921012.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


52. Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, Qian W, Huang J, Mao L, Tong Y, Wang L, Qian J, Jin J: Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma; 2008 Jan;49(1):81-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome.
  • T-cell lymphoma-associated hemophagocytic syndrome (T-LAHS) has been frequently reported in Asian countries and is considered with extremely poor prognosis.
  • To summarize its clinical characteristics and explore its early diagnosis and treatment, we retrospectively analyzed the records of 113 patients with aggressive T cell lymphoma, of which 28 were associated with LAHS.
  • According to WHO classification (2001), 22 cases were classified into peripheral T-cell lymphoma (unspecified), 2 into extranodal NK/T-cell lymphoma, and 4 into systemic anaplastic large cell lymphoma.
  • The elevating rates of serum lactate dehydrogenase (LDH) (100% vs. 55%), ferritin (100% vs. 64%), fasting triglycerides (79% vs. 43%), and hypofibrinogen (43% vs. 14%) levels were higher in the LAHS group than in the no-LAHS group (P < 0.05), so were bone marrow involvement (57% vs. 32%, P < 0.05) and liver dysfunction (40% vs. 13%, P < 0.05).
  • Repeating biopsies of multiple parts of bone marrow may help diagnosis.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / complications. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203016.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


53. Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol; 2006;116(2):90-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
  • We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL).
  • All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years.
  • The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT).
  • However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy


54. Hsieh PP, Tseng HH, Chang ST, Fu TY, Lu CL, Chuang SS: Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan. Leuk Lymphoma; 2006 Jan;47(1):65-70
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of bone: a rare disorder with high frequency of T-cell phenotype in southern Taiwan.
  • Primary non-Hodgkin's lymphoma of bone (PLB) is a rare disorder representing less than 1% of all non-Hodgkin's lymphomas and has rarely been reported in Taiwan.
  • There was male predominance (M:F = 6:1) with a median age of 42 and bone pain (6 patients, 43%) as the most common symptom.
  • Eight cases (57%) were of B-cell phenotype and the remaining 6 (43%), T-cell.
  • Histologically, 7 (50%) were diffuse large B-cell lymphomas (DLBCLs) and 5 (36%) anaplastic large cell lymphomas.
  • Of the 11 patients with follow-up information, 6 (55%) died of disease within 1 year including 5 with T-cell lymphomas, while all the 5 patients surviving over 1 year were of B-cell phenotype.
  • The survival of B-cell lymphomas was significantly better than T-cell tumors (p = 0.016, log-rank test).
  • In summary, this study reported the largest series of PBL in Taiwan and confirmed that the majority was DLBCL and B-cell tumors had more favorable prognosis.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Lineage. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Phenotype. Predictive Value of Tests. Prognosis. Remission Induction. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321829.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


55. Tong H, Ren Y, Qian W, Xiao F, Mai W, Meng H, Jin J: Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int J Hematol; 2009 Oct;90(3):303-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China.
  • We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI.
  • We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL.
  • In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001).
  • The median survival time of the 14 patients subjected to chemotherapy combined with L: -asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days.
  • We conclude that patients with PTCLs with BMI on initial diagnosis usually have hemaphagocytic syndrome and poor prognosis.
  • Patients with anemia on initial diagnosis in the BMI group usually have poor prognosis than those without.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Lymphohistiocytosis, Hemophagocytic / drug therapy. Lymphohistiocytosis, Hemophagocytic / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728028.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7006-34-0 / Asparagine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


56. Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, Takase K, Henzan H, Kato K, Takenaka K, Fukuda T, Harada N, Nagafuji K, Teshima T, Akashi K, Harada M, Eto T, Fukuoka Blood and Marrow Transplantation Group: Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant; 2010 Feb;45(2):311-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.
  • Peripheral T-cell lymphoma (PTCL) is generally characterized by poor prognosis after conventional chemotherapy compared with aggressive B-cell lymphoma.
  • Eleven patients were histologically typed as angioimmunoblastic, nine as anaplastic large-cell lymphoma, seven as natural killer/T-cell lymphoma and twelve as PTCL unspecified.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597416.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M: FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol; 2007 Oct;18(10):1685-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in T-cell and NK-cell neoplasms.
  • BACKGROUND: A growing number of studies demonstrate the utility of (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) in the management of malignant lymphoma.
  • The results of FDG-PET, however, have not been studied extensively for T-cell and natural killer (NK)-cell neoplasms.
  • PATIENTS AND METHODS: We retrospectively evaluated pretreatment FDG-PET scans in 41 patients with T/NK-cell neoplasms diagnosed according to the World Health Organization (WHO) classification.
  • Histological subtypes frequently included were peripheral T-cell lymphoma, unspecified (PTCLu, n = 11), extranodal NK/T-cell lymphoma, nasal type (ENKL, n = 8), primary cutaneous anaplastic large cell lymphoma (C-ALCL, n = 5), and angioimmunoblastic T-cell lymphoma (AILT, n = 4).
  • RESULTS: FDG-PET detected a lymphoma lesion in at least one site in 36 out of 41 patients.
  • The positive rate of FDG-PET for bone marrow involvement was only 20%.
  • CONCLUSION: T/NK-cell neoplasms incorporated in this study were generally FDG-avid except for cutaneous lesions and bone marrow involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716987.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


58. Küpeli S, Varan A, Demir H, Aydin B, Yüce A, Büyükpamukçu M: Association of Helicobacter pylori and childhood lymphoma. J Pediatr Hematol Oncol; 2007 May;29(5):301-4
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Helicobacter pylori and childhood lymphoma.
  • We aimed to estimate the frequency of association between non-Hodgkin lymphoma (NHL) with abdominal, gastric, or intestinal involvement and Helicobacter pylori in childhood.
  • Pathologic diagnosis was made by examining the biopsy samples.
  • Ten had high-grade B-cell lymphoma.
  • First patient had T-cell lymphoma and stage IV disease with involvement in stomach, mediastinum, peripheral lymph nodes, and bone marrow.
  • The second one had anaplastic large cell lymphoma exclusively in abdominal lymph nodes.
  • Last patient had Burkitt lymphoma and stage IV disease, with primary tumor localization in abdominal lymph nodes, liver, and kidneys.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Lymphoma, B-Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483706.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


59. Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, Makimoto A, Kagami Y, Terauchi T, Matsuno Y, Tobinai K: Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol; 2007 Mar;37(3):216-23
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study.
  • BACKGROUND: The incidence of primary bone lymphoma (PBL) is so rare that many of its aspects remain unknown.
  • Although 19 (68%) patients had diffuse large B-cell lymphoma (DLBCL), other histopathological subtypes (three B-lymphoblastic lymphoma, two anaplastic large cell lymphoma, two indolent B-cell lymphoma, one NK/T-cell lymphoma (NTCL) and one Hodgkin lymphoma) were also included.
  • While 68% of patients had stage IV disease, none of them showed bone marrow involvement at their initial diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Hodgkin Disease / pathology. Humans. Lymphoma, B-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472971.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


60. Merlin E, Chabrier S, Verkarre V, Cramer E, Delabesse E, Stéphan JL: Primary leptomeningeal ALK+ lymphoma in a 13-year-old child. J Pediatr Hematol Oncol; 2008 Dec;30(12):963-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leptomeningeal ALK+ lymphoma in a 13-year-old child.
  • A distinct pathologic entity characterized by expression of the anaplastic lymphoma kinase (ALK) protein (hence described as ALK lymphoma) has emerged within the heterogeneous group of CD30 anaplastic large-cell lymphomas.
  • Central nervous system (CNS) involvement is extremely rare in anaplastic large-cell lymphoma.
  • Cerebrospinal fluid was infiltrated with atypical large granular lymphocytes.
  • A frontal lobe biopsy showed a pleomorphic neoplasm diffusely infiltrating the meninges composed of large cells with bizarre nuclei similar to those evidenced in cerebrospinal fluid.
  • Immunohistochemical stains showed diffuse strong positivity for CD8, CD30, anaplastic lymphoma kinase protein: p80 and negative monocyte-macrophage and B cell markers.
  • After a short-term remission with vinblastine, he underwent nonmyeloablative allogeneic bone marrow transplantation, but unfortunately died from multiple organ failure.
  • This case is the first reported occurrence of a primary meningeal ALK lymphoma in a child.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Meningeal Neoplasms / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adolescent. DNA, Neoplasm / analysis. Fatal Outcome. Gene Rearrangement. Genes, T-Cell Receptor gamma / genetics. Humans. Immunophenotyping. Male. Multiple Organ Failure. Receptor Protein-Tyrosine Kinases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131793.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


61. Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG: Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant; 2008 Jul;14(7):741-7
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
  • The peripheral T cell lymphomas (PTCL) carry a worse prognosis compared to B cell non-Hodgkin lymphoma.
  • There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant (AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with conventional therapy.
  • Fifty-three cases were identified consisting of systemic anaplastic large cell (n = 18), PTCL unspecified (n = 17), angioimmunoblastic (n = 9), nasal type extranodal NK/T (n = 7), hepatosplenic (n = 2), and adult T cell leukemia/lymphoma (n = 1).
  • Histology, age, sex, stage, B symptoms, bone marrow involvement, and duration of first response did not significantly affect PFS or OS.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(4):304-11 [15297846.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3334-41 [7538824.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Bone Marrow Transplant. 1999 Jul;24(2):153-61 [10455343.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11 [16785059.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Ann Hematol. 2007 Jun;86(6):435-42 [17256144.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):239-43 [17530000.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1067-74 [17640855.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • (PMID = 18541192.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA049605-15; United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / P01 CA049605-15
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS232367; NLM/ PMC2980839
  •  go-up   go-down


62. Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE: New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res; 2010 Dec 1;16(23):5608-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.
  • Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas.
  • They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas.
  • Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / etiology. Lymphoma, T-Cell, Peripheral / therapy. Therapies, Investigational / trends
  • [MeSH-minor] Animals. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / therapeutic use. Cell Biology. Comprehension. Drug Discovery / methods. Drug Discovery / trends. Gene Expression Profiling. Humans. Molecular Targeted Therapy / methods

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):924-32 [16467107.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Mar;3(3):165-8; quiz 169 [16520806.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3762-73 [16778104.001]
  • [Cites] Blood. 2006 Jul 15;108(2):705-10 [16551968.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):439-47 [17233846.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):746-55 [17234786.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34 [17406867.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):521-5 [17454592.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4655-62 [17311990.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3699-703 [17530023.001]
  • [Cites] Curr Opin Hematol. 2007 Jul;14(4):348-53 [17534160.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2764-9 [17515574.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3109-15 [17577020.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):741-7 [18541192.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1139-43 [18401419.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4500-10 [18628465.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] Leuk Lymphoma. 2008 Sep;49(9):1836-8 [18661402.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4952-7 [18606983.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2079-83 [18689866.001]
  • [Cites] Bone Marrow Transplant. 2008 Dec;42(12):773-81 [18936735.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2514-22 [19293260.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):817-25 [10952788.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4307-12 [11110706.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):185-7 [11328299.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2865-8 [11675364.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):718-28 [11895901.001]
  • [Cites] Med Oncol. 2002;19 Suppl:S27-32 [12180489.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1027-35 [12854905.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2744-54 [12855655.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3737-42 [12881320.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):342-9 [14716770.001]
  • [Cites] Br J Haematol. 2009 May;145(3):344-9 [19245430.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3918-26 [19509169.001]
  • [Cites] Br J Haematol. 2009 Jul;146(2):171-9 [19466965.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4357-64 [19652067.001]
  • [Cites] Am J Health Syst Pharm. 2009 Nov 1;66(21):1890 [19850775.001]
  • [Cites] J Clin Oncol. 2009 Nov 10;27(32):5410-7 [19826128.001]
  • [Cites] Leukemia. 2010 Jan;24(1):229-32 [19776763.001]
  • [Cites] Br J Haematol. 2010 Jan;148(2):256-67 [19874311.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):447-55 [20141439.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1591-8 [20177026.001]
  • [Cites] Ann Oncol. 2010 Apr;21(4):860-3 [19887465.001]
  • [Cites] Blood. 2010 Apr 1;115(13):2578-85 [19965662.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):602-6 [2783489.001]
  • [Cites] Cell. 1992 Feb 7;68(3):421-7 [1310894.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5335-41 [7585597.001]
  • [Cites] Blood. 1996 Jan 1;87(1):284-91 [8547653.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1367-72 [9264394.001]
  • [Cites] Blood. 1998 Jan 15;91(2):399-405 [9427692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6791-6 [9618491.001]
  • [Cites] Ann Oncol. 1998 Dec;9(12):1351-3 [9932168.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):676-84 [15613699.001]
  • (PMID = 21138864.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS236831; NLM/ PMC3058794
  •  go-up   go-down


63. Casulo C, Horwitz S: Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting? Curr Oncol Rep; 2010 Nov;12(6):374-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?
  • Peripheral T-cell lymphomas (PTCL) are rare and aggressive subtypes of non-Hodgkin's lymphoma.
  • Compared to B cell lymphomas, the immunologic phenotype of PTCL portends a poorer prognosis, with the exception of anaplastic large cell lymphoma bearing the anaplastic lymphoma kinase protein.
  • Consequently, high-dose chemotherapy and autologous stem cell transplantation (ASCT) have been actively studied in both the relapsed and upfront setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Lymphoma, B-Cell / therapy. Randomized Controlled Trials as Topic. Risk Factors. Secondary Prevention. Survival Rate. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1768-75 [14630683.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):405-10 [14676776.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):687-96 [6234983.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1783-90 [2585020.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2437-41 [16216001.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):35-9 [16308699.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Haematologica. 2007 Feb;92(2):271-2 [17296587.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):239-43 [17530000.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] Ann Oncol. 2008 May;19(5):958-63 [18303032.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):106-13 [19029417.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25 [19135950.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Ann Oncol. 2010 Apr;21(4):860-3 [19887465.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • (PMID = 20737300.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS577493; NLM/ PMC4075438
  •  go-up   go-down


64. Pich A, Fraire F, Fornari A, Bonino LD, Godio L, Bortolin P, Chiusa L, Palestro G: Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study. Eur J Haematol; 2006 May;76(5):392-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study.
  • Intrasinusoidal infiltration (ISI) is a pattern of invasion that is rarely found on bone marrow (BM) biopsies, and is considered as a hallmark of splenic marginal zone cell lymphoma (SMZL).
  • We analysed BM biopsies showing intrasinusoidal infiltration from 54 consecutive patients with different types of lymphoma to verify if ISI quantity was a diagnostic criterion for SMZL.
  • There were 35 primary splenic lymphoma (PSL) and 19 non-PSL; 28 SMZL, three non-splenic MZL, six mantle cell, six small lymphocytic, four follicular, four diffuse large B cell, one peripheral T cell, one lymphoplasmacytic and one anaplastic large-cell lymphoma.
  • No difference in ISI quantity was found among the lymphoma subtypes, either in PSL (P = 0.74) or non-PSL (P = 0.3).
  • [MeSH-major] Bone Marrow / pathology. Bone Marrow Neoplasms / secondary. Lymphoma, Non-Hodgkin / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Bone Marrow Examination / methods. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Organ Size

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2006 Oct;77(4):360; author reply 361 [16961729.001]
  • (PMID = 16480431.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


65. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, Sobecks R, Andresen S, Hsi ED, Pohlman B, Sweetenham JW: Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant; 2007 Aug;40(3):239-43
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
  • The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined.
  • Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL.
  • Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL.
  • Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease.
  • These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / therapy. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Aged. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / therapy. Male. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17530000.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


66. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M: Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant; 2010 Feb;16(2):223-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents.
  • We examined the role of hematopoietic stem cell transplantation (HSCT) for patients aged< or =18 years with refractory or recurrent Burkitt (n=41), lymphoblastic (n=53), diffuse large B cell (DLBCL; n=52), and anaplastic large cell lymphoma (n=36), receiving autologous (n=90) or allogeneic (n=92; 43 matched sibling and 49 unrelated donor) HSCT in 1990-2005.
  • Allogeneic donor HSCT was more likely to use irradiation-containing conditioning regimens, bone marrow (BM) stem cells, be performed in more recent years, and for lymphoblastic lymphoma.
  • After adjusting for disease status, 5-year EFS were similar after allogeneic and autologous HSCT for DLBCL (50% vs 52%), Burkitt (31% vs 27%), and anaplastic large cell lymphoma (46% vs 35%).
  • However, EFS was higher for lymphoblastic lymphoma, after allogeneic HSCT (40% vs 4%; P < .01).
  • Predictors of EFS for progressive or recurrent disease after HSCT included disease status at HSCT and use of allogeneic donor for lymphoblastic lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Hematol Oncol Clin North Am. 1999 Oct;13(5):1091-112, viii-ix [10553263.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):897-903 [19139435.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):965-8 [11298592.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2390-6 [11331317.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Cytotherapy. 2002;4(3):253-8 [12194721.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):53-63 [12508269.001]
  • [Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Blood. 1992 Dec 1;80(11):2938-42 [1450419.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2003-6 [8471762.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):353-9 [7599558.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2921-30 [9376572.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):70-6 [15368550.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):541-7 [15659500.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):176-82 [16611309.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):787-94 [16932891.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):188-92 [18428432.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • (PMID = 19800015.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-14; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / CA076518-14; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217814; NLM/ PMC2911354
  •  go-up   go-down


67. Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y: [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. Ai Zheng; 2007 Apr;26(4):418-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
  • BACKGROUND & OBJECTIVE: Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology.
  • Immunophenotyping will make diagnosis more precise through analyzing the origin and differentiation status of tumor, which is necessary for treatment and prognosis prediction.
  • This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM).
  • METHODS: Bone marrow specimens from 112 patients with lymphocytic leukemia or NHL with bone marrow involvement were detected by FCM using antibodies of T, B and myeloid cell series.
  • RESULTS: In 45 cases of precursor B lymphoblastic leukemia/lymphoma (B-ALL/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20.
  • In 32 cases of precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR.
  • Among the 35 cases of mature B-cell malignancies, 17 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell lymphoma (DLBCL) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's lymphoma (BL) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell lymphoma (MCL) expressed CD5, CD19, CD20, and HLA-DR.
  • Among the 10 mature T-cell malignancies, 5 cases of unspecialied peripheral T-cell lymphoma (PTCL) mainly expressed sCD3, CD5 and CD7, CD4 or CD8; 1 case of anaplastic large cell lymphoma (ALCL) expressed sCD3 and HLA-DR; 4 cases of NK/T-cell malignancies expressed CD56 and HLA-DR, CD4 or CD8 or CD7.
  • CONCLUSION: Multiparameter FCM can not only provide data of cell lineage and differentiation status but also detect phenotypic aberrancies, which is helpful for minimal residual disease detecting.
  • [MeSH-major] Antigens, CD / analysis. Bone Marrow / immunology. Immunophenotyping. Leukemia, Lymphoid / immunology. Lymphoma, Non-Hodgkin / immunology

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430665.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens
  •  go-up   go-down


68. Sahni CS, Desai SB: Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000). Leuk Lymphoma; 2007 Jan;48(1):122-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000).
  • The frequency of various subtypes of non-Hodgkin's lymphoma (NHL) differs in various regions worldwide.
  • B- and T-cell NHL constituted 79.3% and 18.8% of cases.
  • Diffuse large B-cell lymphoma (DLBL) was the most common subtype (50.2%).
  • A lower frequency of follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma (MCL) was noted compared to that observed in the developed countries, whereas a lower frequency of peripheral T-cell lymphoma - not otherwise specified (PTCL-NOS) and extranodal NK/T-cell lymphoma was seen compared to that in the other Asian countries.
  • A higher frequency of DLBL and precursor T-lymphoblastic leukemia/lymphoma was noted.
  • Extranodal and bone marrow involvement in MCL and PTCL-NOS was less frequent.
  • Anaplastic variant of DLBL was noted in 21.5% of all DLBLs.
  • Null/T-cell anaplastic large cell lymphoma presented in the older age.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325856.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Smith ZA, Sedrak MF, Khoo LT: Primary bony non-Hodgkin lymphoma of the cervical spine: a case report. J Med Case Rep; 2010;4:35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bony non-Hodgkin lymphoma of the cervical spine: a case report.
  • INTRODUCTION: Non-Hodgkin lymphoma primarily originating from the bone is exceedingly rare.
  • To our knowledge, this is the first report of primary bone lymphoma presenting with progressive cord compression from an origin in the cervical spine.
  • Histological analysis demonstrated an aggressive anaplastic large cell lymphoma.
  • CONCLUSION: Isolated primary bony lymphoma of the spine is exceedingly rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1992 May;30(5):675-80 [1584377.001]
  • [Cites] Radiother Oncol. 1992 May;24(1):14-20 [1620883.001]
  • [Cites] Br J Cancer. 1991 Jan;63(1):126-9 [1989650.001]
  • [Cites] Clin Radiol. 1991 Feb;43(2):95-102 [2004521.001]
  • [Cites] Can Assoc Radiol J. 1989 Apr;40(2):75-9 [2702504.001]
  • [Cites] AMA Arch Surg. 1954 Jul;69(1):66-76 [13170925.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2699-707 [7139563.001]
  • [Cites] J Neurosurg. 1980 Dec;53(6):741-8 [7441333.001]
  • [Cites] Cancer. 1994 Feb 15;73(4):1194-9 [8313322.001]
  • [Cites] Rofo. 1993 Jun;158(6):589-93 [8507852.001]
  • [Cites] Cancer. 1986 Nov 1;58(9):2120-4 [3756827.001]
  • (PMID = 20205845.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825519
  •  go-up   go-down


70. Tang YJ, Tang JY, Pan C, Xue HL, Chen J, Shen SH, Dong L, Zhou M, Wang YP, Gu LJ, Jiang H, Ye QD: [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children]. Zhonghua Er Ke Za Zhi; 2009 Sep;47(9):687-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children].
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) presenting as mediastinal mass is usually progressive and may cause severe respiratory distress and death.
  • Their clinical characteristics, pathologic classification, diagnosis, outcome of different treatment protocol were retrospectively analyzed.
  • Diagnosis was established on pathology that was achieved by mediastinal mass or peripheral lymph nodes biopsy, while some were diagnosed based on bone marrow or pleural effusion cytology study and immunophenotyping.
  • Of them, 24 were lymphoblastic lymphoma and 3 were anaplastic large cell lymphoma.
  • Nine patients were diagnosed by cytological study of bone marrow aspiration or pleural fluid.
  • All the 36 cases were T-cell type.
  • CONCLUSION: Establishment of a diagnosis as soon as possible was important to reduce the mortality and improve long term survival of patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Mediastinal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021793.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


71. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, Kurtin PJ, Dogan A: Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia; 2009 Mar;23(3):574-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
  • In contrast to myeloid and B-cell neoplasms, translocations in peripheral T-cell lymphomas (PTCLs) are poorly understood.
  • IRF4 translocations exist in myeloma and some B-cell lymphomas, but have not been reported earlier in PTCLs.
  • Two cases with t(6;14)(p25;q11.2) had translocations between IRF4 and the T-cell receptor-alpha (TCRA) locus.
  • Both were cytotoxic PTCLs, unspecified (PTCL-Us) involving bone marrow and skin.
  • In total, 8 of the remaining 10 cases were cutaneous anaplastic large-cell lymphomas (ALCLs) without TCRA rearrangements (57% of cutaneous ALCLs tested).
  • Cytotoxic PTCL-Us involving bone marrow and skin and containing IRF4/TCRA translocations might represent a distinct clinicopathologic entity.
  • Detecting these translocations may be useful in lymphoma diagnosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):1-9 [11520558.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leukemia. 2006 Feb;20(2):313-8 [16341044.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):124-32 [17387297.001]
  • [Cites] J Pathol. 2007 Sep;213(1):99-105 [17582237.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Nov;46(11):1011-8 [17696193.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4293-7 [17709797.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):516-26 [18275429.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2516-20 [17975015.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):557-63 [18234282.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3867-71 [18235046.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Br J Dermatol. 2008 Jun;158(6):1280-7 [18410414.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1268-72 [17989713.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1139-43 [18401419.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):178-85 [18628085.001]
  • [Cites] Histopathology. 2000 Feb;36(2):136-44 [10672058.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):773-9 [12428799.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):176-85 [12696066.001]
  • [Cites] Histopathology. 2003 Nov;43(5):462-9 [14636272.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Leuk Res. 1985;9(9):1139-48 [3877852.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] J Invest Dermatol. 1997 Nov;109(5):636-40 [9347791.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):114-21 [9598798.001]
  • [Cites] Hum Pathol. 1999 Feb;30(2):228-36 [10029454.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):319-29 [10478136.001]
  • [Cites] Leukemia. 2005 Jan;19(1):77-82 [15510210.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3058-65 [15626743.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2247-53 [16193085.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:131-5 [10707795.001]
  • (PMID = 18987657.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P50 CA097274-07; United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ NIHMS70248; NLM/ PMC2656414
  •  go-up   go-down


72. Halaburda K, Nasiłowska-Adamska B, Grabarczyk P, Szczepiński A, Szpila T, Warzocha K, Mariańska B: Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab. Ann Transplant; 2007;12(2):37-40
MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
  • Also, in those who develop reactivation short time before stem cell transplantation the risk of fatal complications is extremely high.
  • CASE REPORT: We describe a 21-year-old patient with anaplastic large T-cell lymphoma who developed CMV reactivation after alemtuzumab treatment and received high-dose chemotherapy with autologous stein cell transplantation for progressive disease and severe bone marrow aplasia.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects. Cytomegalovirus Infections / diagnosis. DNA, Viral / blood. Pneumonia, Viral / diagnosis. Polymerase Chain Reaction
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Fatal Outcome. Female. Humans. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / surgery. Stem Cell Transplantation. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18173065.001).
  • [ISSN] 1425-9524
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / DNA, Viral; 3A189DH42V / alemtuzumab
  •  go-up   go-down


73. Zuo Z, Liu WP, Tang Y, Bi CF, Wang XQ, Zhang WY, Yang QP, Zou LQ: [Solitary plasmacytoma of bone: a clinicopathologic, immunohistochemical and immunoglobulin gene rearrangement study]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):177-82
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary plasmacytoma of bone: a clinicopathologic, immunohistochemical and immunoglobulin gene rearrangement study].
  • OBJECTIVE: To investigate clinicopathologic features of solitary plasmacytoma of bone (SPB) and the role of immuno-phenotype and immunoglobulin gene rearrangement detection in the diagnosis and differential diagnosis of SPB.
  • Clinical manifestations were closely related to the anatomic sites involved, such as pain due to bone destruction, symptoms and signs caused by compression of spinal cord or nerve root, and pathological fracture.
  • Immunohistochemically, the neoplastic cells expressed two or more plasma cell antigens, including CD138, CD38 and PC, but no CD19 and CD20.
  • CONCLUSIONS: SPB is a rare tumor with bone pain as the most common presenting symptom due to bone destruction.
  • The diagnosis of EMP can only be established after exclusion of an extramedullay invasion by MM.
  • Immunophenotype and IgH gene rearrangement analysis play important roles in the diagnosis of SPB.
  • [MeSH-major] Bone Neoplasms / pathology. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Plasmacytoma / pathology. Syndecan-1 / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD38 / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunophenotyping. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Multiple Myeloma / pathology. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450765.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Syndecan-1; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


74. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol; 2005 May;129(3):366-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
  • The World Health Organization (WHO) lymphoma classification recognises anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma (AIL) and peripheral T-cell lymphoma, unspecified (PTCU) as nodal mature T-cell lymphomas.
  • To a large extent, the IPI score explains the differences in survival between histological subtypes of nodal mature T-cell lymphomas.
  • The IPI may therefore be used for risk stratification in clinical trials to identify patients who would benefit most from new treatment strategies, such as high-dose chemotherapy followed by stem cell or bone marrow transplantation.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Cause of Death. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842660.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Horny HP, Sotlar K, Valent P: Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology; 2010;77(4):169-80
Genetic Alliance. consumer health - Systemic mastocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
  • Diagnosis of systemic mastocytosis (SM) is mainly based on the morphological demonstration of compact mast cell infiltrates in various tissue sites.
  • In almost all patients such infiltrates are detected in the bone marrow.
  • Reliable immunohistochemical markers for the diagnosis and grading of SM have been established, but various differential diagnoses including myeloproliferative neoplasms, basophilic and eosinophilic leukemias may be very difficult to delineate.
  • Even more challenging is the recognition of hematological neoplasms with signs of mast cell differentiation but not fulfilling diagnostic criteria for SM, especially the rare myelomastocytic leukemia.
  • It is also important to separate the reactive state of mast cell hyperplasia from indolent variants of SM, especially those with a very low degree of bone marrow infiltration and absence of compact mast cell infiltrates.
  • When the lymphocytic component of the SM infiltrate is very prominent, SM may be confused with an indolent lymphoma, especially lymphoplasmacytic lymphoma which almost always shows a marked reactive increase in mast cells.
  • Thus, anaplastic large cell lymphoma or Hodgkin's disease may first be considered rather than SM.
  • Therefore, such skin lesions are an important clue to the correct diagnosis in these patients.
  • However, in aggressive or leukemic SM skin lesions are usually absent and then the correct diagnosis relies on an appropriate investigation of bone marrow biopsy specimens using both SM-related immunohistochemical markers (tryptase, KIT, CD25, CD30) but also markers excluding potential differential diagnoses.
  • Investigation for presence of the activating KIT point mutation D816V is very helpful to establish a correct diagnosis of SM in all the difficult cases exhibiting a low degree of bone marrow infiltration or puzzling morphological findings.
  • [MeSH-major] Bone Marrow / pathology. Mastocytosis, Systemic / diagnosis
  • [MeSH-minor] Adult. Basophils / immunology. Basophils / pathology. Biopsy. Diagnosis, Differential. Humans. Mast Cells / immunology. Mast Cells / pathology. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / immunology. Point Mutation. Urticaria Pigmentosa / diagnosis. Urticaria Pigmentosa / genetics. Urticaria Pigmentosa / pathology

  • Genetic Alliance. consumer health - Mast cell disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20616612.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


76. Zhu H, Zhou XG: [Morphologic diversity of plasma cell neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2010 Aug;39(8):528-31
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic diversity of plasma cell neoplasms].
  • OBJECTIVE: To investigate the architectural and cytological variations of plasma cell neoplasms, and discuss the diagnosis and differential diagnosis.
  • METHODS: Histological and immunohistochemical examinations were used to study the morphologic and immunophenotypic features of 46 cases of plasma cell neoplasms.
  • Tumor cells were composed of anaplastic cells, histocytoid cells and spindle cells in each one case, respectively.
  • CONCLUSIONS: Except for the common architecture and cytology in plasma cell tumor, unusual morphology may appear.
  • Thus, pay attention to distinguish from lymphoma such as small lymphocytic lymphoma and anaplastic large cell lymphoma, pooly differentiated carcinoma, clear cell carcinoma or Signet-ring cell carcinoma, sarcoma, etc.
  • [MeSH-major] Bone Neoplasms / pathology. Mouth Neoplasms / pathology. Neoplasms, Plasma Cell / pathology. Nose Neoplasms / pathology. Plasmacytoma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055031.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD79; 0 / CD79A protein, human; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


77. Fuehrer M, Gerusel-Bleck M, Konstantopoulos N, Bender-Goetze C, Walther JU: FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children. Int J Mol Med; 2005 Feb;15(2):291-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children.
  • After stem cell transplantation (SCT) close follow-up of chimerism and/or clonal disease markers is essential for early treatment of graft failure or relapse.
  • Diagnoses were ALL (8), AML (6), MDS (2), CML (2), large cell anaplastic lymphoma (1) and SAA (4).
  • Eighteen children were transplanted from sex-mismatched donors, seven among them had shown a clonal marker at diagnosis.
  • The presence of host cells and/or clonal markers established at diagnosis by conventional karyotyping was followed up after SCT at regular intervals by FISH.
  • FISH allowed identification of cell origin in non-hematologic material (spinal fluid, pericardial effusion).
  • [MeSH-major] Bone Marrow Cells / metabolism. Bone Marrow Transplantation / methods. Chimerism. In Situ Hybridization, Fluorescence / methods. Stem Cell Transplantation / methods. Transplantation Chimera
  • [MeSH-minor] Bone Marrow / pathology. Female. Humans. Karyotyping. Male. Polymerase Chain Reaction. Recurrence. Remission Induction. Sensitivity and Specificity. Sex Factors. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647846.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


78. Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M: Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol; 2008 Sep;26(3):152-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
  • We studied the clinico-pathologic features and treatment outcome of patients with peripheral T-cell lymphoma (PTCL).
  • This study included 215 patients with T/natural killer (NK)-cell lymphoma, including 59 with PTCL-unspecified (PTCL-U), 42 with angioimmunoblastic T-cell lymphoma (AILT) and 20 with anaplastic large-cell lymphoma (ALCL).
  • The 5-year PFS and OS rates among patients who received CHOP therapy, CyclOBEAP [cyclophosphamide (CPA), vincristine (VCR), bleomycine, etoposide, doxorubicin (DXR), prednisone (PDN)] therapy or autologous stem cell transplantation were: 22 and 25.7%, 59 and 61.7% or 33.3 and 60%, respectively.
  • These results indicate that the presence of bone marrow (BM) involvement is an independent prognostic factor which may predict both OS and PFS.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18395866.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, Zuckerman DS, Sohani AR: Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. J Hematop; 2009;2(4):237-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast involvement by lymphoma is uncommon and poses challenges in diagnosis.
  • The first case, ALK-negative anaplastic large-cell lymphoma involving a seroma associated with a breast implant, is an emerging clinicopathologic entity.
  • Anaplastic large-cell lymphoma has been identified in association with breast implants and seroma formation relatively recently.
  • The second case, hairy cell leukemia involving the breast and ipsilateral axillary sentinel lymph node, is, to our knowledge, the first reported case of hairy cell leukemia involving the breast at the time of diagnosis.
  • While a localized bone lesion was present at time of diagnosis, bone marrow involvement was relatively mild in comparison to that seen in the breast and lymph node.
  • In the first case, lymphoma occurred in a clinical setting where malignancy was unsuspected, highlighting the importance of careful morphologic evaluation of paucicellular samples, as well as awareness of rare clinicopathologic entities, in avoiding a misdiagnosis of a benign inflammatory infiltrate.
  • Knowledge of the patient's concurrent diagnosis of hairy cell leukemia involving the bone marrow and bone helped avoid a misdiagnosis of carcinoma rather than lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Medica (Hradec Kralove). 2003;46(4):175-7 [14965169.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73 [16990107.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1511-20 [18704988.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • [Cites] Cancer. 1979 Apr;43(4):1339-49 [445334.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):605-9 [2803932.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1280-4 [3411340.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):113-8 [4565899.001]
  • [Cites] Cancer. 1974 May;33(5):1399-410 [4823484.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):370-80 [6505704.001]
  • [Cites] Plast Reconstr Surg. 1994 Oct;94(5):628-33; discussion 634-6 [7938285.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):505-7 [8604821.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):819-27 [11075871.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • (PMID = 20309431.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2798933
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Anaplastic lymphoma kinase / Breast / Breast implant / Hairy cell leukemia / Primary breast lymphoma / Seroma / T-cell neoplasm
  •  go-up   go-down


80. Desouki MM, Post GR, Cherry D, Lazarchick J: PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clin Med Res; 2010 Jul;8(2):84-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.
  • PAX-5, a transcription factor expressed throughout B-cell maturation, is detected in most B-cell neoplasms including those that lack expression of mature B-cell markers, such as classical Hodgkin lymphoma (cHL), B-lymphoblastic leukemia and B-cell lymphomas following rituximab therapy.
  • The lack of PAX-5 expression in most CD30-positive non-hematopoietic malignancies (embryonal carcinoma and seminoma) and T-cell lymphomas, such as anaplastic large cell lymphoma (ALCL), suggests that the absence of PAX-5 may be used to confirm non-B-cell lineage.
  • DESIGN: Diagnostic lymph node, decalcified core bone marrow biopsies and tissue sections from 111 archived paraffin-embedded tissue blocks and a tissue lymphoma microarray were immunostained using a monoclonal antibody to PAX-5.
  • RESULTS: Nuclear PAX-5 immunoreactivity was detected in 88% (36/41) of Hodgkin lymphoma, all cases of diffuse large B-cell lymphoma (n=72), small B-cell lymphomas (n=5), B-lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia with B-cell lineage (n=5).
  • PAX-5 was not detected in ALCL (n=22), T-cell lymphoblastic leukemia/lymphoma, mixed phenotype acute leukemia with T-cell lineage (n=5), acute myeloid leukemia (n=4), carcinoid tumors with typical morphology (n=5), melanoma (n=3), and undifferentiated/metastatic tumors (n=8).
  • Non-neoplastic bone marrow sections showed scattered nuclear staining in small B-cell lymphocytes/hematogones.
  • CONCLUSION: Overall, our results demonstrate that including PAX-5 in a panel with other immunomarkers helps establish B-cell lineage and increases diagnostic yield.
  • [MeSH-major] B-Cell-Specific Activator Protein / analysis. Biomarkers, Tumor / analysis. Lymphoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hodgkin Disease / diagnosis. Humans. Immunohistochemistry. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2001 Sep;114(4):881-3 [11564080.001]
  • [Cites] Immunity. 2001 Jun;14(6):779-90 [11420047.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2335-41 [12613521.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4620-5 [12907641.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1839-46 [15155532.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7399-404 [15492262.001]
  • [Cites] Genomics. 1991 Oct;11(2):424-34 [1685142.001]
  • [Cites] Blood. 1992 Jul 15;80(2):470-7 [1378322.001]
  • [Cites] Genes Dev. 1992 Sep;6(9):1589-607 [1516825.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1308-16 [9694719.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):611-5 [10100713.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jan;129(1):32-8 [15628906.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):687-92 [15832095.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1542-9 [16056244.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):1010-8 [16648862.001]
  • [Cites] Am J Clin Pathol. 2006 Aug;126(2):235-40 [16891199.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):534-44 [16938666.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1003-8 [17016584.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):798-804 [17050077.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1127-38 [17577776.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):871-7 [17529924.001]
  • [Cites] Lab Invest. 2009 Mar;89(3):301-14 [19139719.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):775-80 [19145202.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):709-14 [16837628.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1343-50 [12360049.001]
  • (PMID = 20660931.001).
  • [ISSN] 1554-6179
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / PAX5 protein, human
  • [Other-IDs] NLM/ PMC2910102
  •  go-up   go-down


81. Simon T, Kohlhase J, Wilhelm C, Kochanek M, De Carolis B, Berthold F: Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. Am J Med Genet A; 2010 Jun;152A(6):1575-9
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He subsequently developed large cell anaplastic T cell lymphoma at the age of 9 years, diffuse large cell B lymphoma and osteosarcoma when he was 14 years old, and finally acute lymphatic leukemia when he was 21 years old.
  • The most remarkable clinical features are young age, spontaneous remission of diffuse large cell lymphoma, and severe CNS and skin toxicity of cytotoxic treatment.
  • [MeSH-major] Bone Neoplasms / genetics. Leukemia, Large Granular Lymphocytic / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Osteosarcoma / genetics. RecQ Helicases / genetics. Rothmund-Thomson Syndrome / genetics


82. Snyder RL: Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use. Am J Health Syst Pharm; 2007 Jun 1;64(11):1163-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The successful resumption of high-dose methotrexate in a 13-year-old boy with recurrent anaplastic large-cell lymphoma (ALCL) who suffered renal dysfunction after a 24-hour infusion of high-dose methotrexate and required treatment with carboxypeptidase G(2) (CPDG(2) ) is described.
  • Recurrent ALCL was diagnosed, and treatments were initiated based on branch K3 of the protocol published in the non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster (NHL-BFM) trial 90.
  • [MeSH-minor] Adolescent. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local. Retreatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519458.001).
  • [ISSN] 1079-2082
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


83. Magro CM, Porcu P, Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN: Cutaneous CD4+ CD56+ hematologic malignancies. J Am Acad Dermatol; 2010 Aug;63(2):292-308
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients 1 and 2 were elderly men exhibiting an acute onset of skin, bone-marrow, and peripheral blood involvement, both dying of their disease within less than 12 months.
  • CD3(+) phenotype and a clonal T-cell receptor beta rearrangement indicated categorization as a CD4(+) natural killer T-cell lymphoma.
  • Patient 3 developed a CD56(+) anaplastic large cell lymphoma and is without disease after excision and radiation.
  • [MeSH-minor] Adult. Aged. Biopsy. Dendritic Cells / metabolism. Dendritic Cells / pathology. Fatal Outcome. Humans. Immunophenotyping. Killer Cells, Natural / metabolism. Killer Cells, Natural / pathology. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / pathology. Leukemia, T-Cell / metabolism. Leukemia, T-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / pathology. Male. Middle Aged. Mycosis Fungoides / metabolism. Mycosis Fungoides / pathology. Sarcoma, Myeloid / metabolism. Sarcoma, Myeloid / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20541283.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56
  •  go-up   go-down


84. Cwiklińska M, Czogała M, Balwierz W, Hnatko-Kołacz M, Moryl-Bujakowska A, Malinowska I, Sładek M, Wieczorek M, Fyderek K, Matysiak M, Rygielska M, Sierhej I: [Hemophagocytic syndrome in children with different underlying conditions]. Przegl Lek; 2010;67(6):430-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 3 cases HS was associated with infections (EBV, CMV, Bacillus Calmette Guerin - BCG), in 1 child with non-Hodgkin anaplastic large cell lymphoma (ALCL), in 1 patients probably with side effect of antiepileptic drug.
  • Patient with ALCL was treated with chemotherapy and allogeneic stem cell transplantation.
  • In case of prolonged fever, splenomegaly and cytopenia diagnosis of HS should be considered.
  • Following tests are recommended: complete blood count, ferritin, triglycerides, fibrinogen, bone marrow aspiration and NK cell assessment.
  • Early diagnosis of HS and underlying condition is crucial to start lifesaving therapy.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / etiology
  • [MeSH-minor] Adolescent. Anticonvulsants / adverse effects. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Magnetic Resonance Imaging. Male. Virus Diseases / complications. Virus Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344776.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


85. Ziarkiewicz-Wróblewska B, Górnicka B, Suleiman W, Ołdakowska-Jedynak U, Wróblewski T, Bogdańska M, Ziółkowski J, Nowacka-Cieciura E, Foroncewicz B, Pileri SA, Durlik M, Paczek L, Krawczyk M, Wasiutyński A: Posttransplant lymphoproliferative disorder: morphological picture and diagnostic difficulties. Transplant Proc; 2006 Jan-Feb;38(1):168-72
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posttransplant lymphoproliferative disorder (PTLD) is a well-known complication of both solid organ and bone marrow transplantation.
  • Among the lymphomas, we observed three diffuse large B-cell lymphoma (DLBCL); one mantle lymphoma; and one Hodgkin lymphoma-like PTLD.
  • In the one case of plasmacytic hyperplasia, the lymph node morphology was atypical with atrophy of lymphoid components accompanying plasma cell proliferation.
  • The most difficult case was a rare Hodgkin lymphoma-like PTLD, which was diagnosed only by a bone marrow biopsy.
  • Because of its noncharacteristic immunophenotype, it was primarily diagnosed as an anaplastic lymphoma of the T-cell type.
  • After additional immunohistochemical studies (BOB and OCT2), we established the final diagnosis of Hodgkin lymphoma-like PTLD.
  • [MeSH-major] Heart Transplantation / adverse effects. Kidney Transplantation / adverse effects. Liver Transplantation / adverse effects. Lymphoproliferative Disorders / diagnosis
  • [MeSH-minor] Adult. Antigens, CD / immunology. Female. Follow-Up Studies. Hodgkin Disease / diagnosis. Humans. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Prognosis. Time Factors

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504694.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


86. Schlaak M, Renner R, Treudler R, Harth W, Poenisch W, Kauer F, Grunewald S, Wittekind C, Simon JC: CD30+ anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with an unusual translocation t(11;22). Br J Dermatol; 2008 Jul;159(1):240-2
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30+ anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with an unusual translocation t(11;22).
  • [MeSH-major] Bone Neoplasms / genetics. Chromosomes, Human, Pair 11 / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 22 / genetics. Diagnosis, Differential. Humans. Male. Phenotype. Sarcoma, Ewing / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489597.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down






Advertisement